Compare GILD & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GILD | NVO |
|---|---|---|
| Founded | 1987 | 1923 |
| Country | United States | Denmark |
| Employees | N/A | 69500 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 173.9B | 166.1B |
| IPO Year | 2001 | N/A |
| Metric | GILD | NVO |
|---|---|---|
| Price | $138.88 | $37.93 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 18 | 11 |
| Target Price | ★ $147.89 | $51.00 |
| AVG Volume (30 Days) | 4.9M | ★ 13.6M |
| Earning Date | 04-24-2026 | 05-06-2026 |
| Dividend Yield | 2.36% | ★ 3.42% |
| EPS Growth | ★ 1684.21 | N/A |
| EPS | ★ 6.78 | N/A |
| Revenue | ★ $24,689,000,000.00 | N/A |
| Revenue This Year | $4.65 | N/A |
| Revenue Next Year | $5.96 | $3.88 |
| P/E Ratio | $20.48 | ★ $13.60 |
| Revenue Growth | ★ 9.98 | N/A |
| 52 Week Low | $95.30 | $35.12 |
| 52 Week High | $157.29 | $81.44 |
| Indicator | GILD | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 45.19 | 47.20 |
| Support Level | $133.89 | $35.49 |
| Resistance Level | $141.70 | $39.58 |
| Average True Range (ATR) | 3.09 | 1.00 |
| MACD | 0.27 | 0.55 |
| Stochastic Oscillator | 54.63 | 85.15 |
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.